- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05169567
이전에 치료한 유방암에서 아베마시클립(LY2835219) + 풀베스트란트와 위약 + 풀베스트란트 비교 (postMONARCH)
postMONARCH: CDK4 및 6 억제제 및 내분비계 진행 후 HR+, HER2-, 진행성 또는 전이성 유방암 환자를 대상으로 아베마시클립 플러스 풀베스트란트와 위약 플러스 풀베스트란트의 효능을 비교하기 위한 무작위, 이중 맹검, 위약 대조, 3상 연구 요법
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
확장된 액세스
연락처 및 위치
연구 장소
-
-
-
Thessaloniki, 그리스, 546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai, Achaḯa, 그리스, 26504
- University Hospital of Patras
-
-
Attikí
-
Athens, Attikí, 그리스, 115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion, Irakleío, 그리스, 711 10
- University General Hospital of Heraklion
-
-
-
-
-
Kaohsiung City, 대만, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, 대만, 231
- Taipei Tzu Chi General Hospital
-
Taipei, 대만, 11217
- Taipei Veterans General Hospital
-
Taipei, 대만, 10449
- Mackay Memorial Hospital
-
Taoyuan, 대만, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan, Tainan, 대만, 71004
- Chi Mei Medical Center
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, 대한민국, 13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], 대한민국, 02841
- Korea University Anam Hospital
-
Seoul, Seoul-teukbyeolsi [Seoul], 대한민국, 08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu, Taegu-Kwangyǒkshi, 대한민국, 41404
- Kyungpook National University Chilgok Hospital
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, 덴마크, 2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning, Central Jutland, 덴마크, 7400
- Regionshospitalet Gødstrup
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, 멕시코, 21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana, Estado de Baja California, 멕시코, 22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara, Jalisco, 멕시코, 45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey, Nuevo León, 멕시코, 64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City, San Luis Potosí, 멕시코, 78209
- Oncologico Potosino, S.C.
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale, Arkansas, 미국, 72762
- Highlands Oncology Group
-
-
California
-
Fullerton, California, 미국, 92835
- Providence Medical Foundation
-
Los Alamitos, California, 미국, 90720
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, 미국, 90033
- Keck School of Medicine of USC
-
Los Angeles, California, 미국, 90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica, California, 미국, 90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar, California, 미국, 91342
- Olive View-UCLA Medical Center
-
Torrance, California, 미국, 90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier, California, 미국, 90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver, Colorado, 미국, 80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers, Florida, 미국, 33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood, Florida, 미국, 33024
- Millennium Oncology Research Clinic
-
Miami, Florida, 미국, 33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola, Florida, 미국, 32503
- Woodlands Medical Specialists, PA
-
Sarasota, Florida, 미국, 34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach, Florida, 미국, 33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Winship Cancer Institute, Emory University
-
Gainesville, Georgia, 미국, 30501
- Northeast Georgia Medical Center
-
Macon, Georgia, 미국, 31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey, Illinois, 미국, 60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles, Louisiana, 미국, 70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston, Maine, 미국, 04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, 미국, 21237
- Mfsmc-Hjwci
-
Clinton, Maryland, 미국, 20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, 미국, 02215
- Dana Farber Cancer Institute
-
Danvers, Massachusetts, 미국, 01923
- MGH Northshore Cancer Center
-
Fairhaven, Massachusetts, 미국, 02719
- Southcoast Centers for Cancer Care
-
Foxborough, Massachusetts, 미국, 02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen, Massachusetts, 미국, 01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford, Massachusetts, 미국, 01757
- Dana Farber Cancer Institute
-
Newton, Massachusetts, 미국, 02462
- Mass General Cancer Center
-
South Weymouth, Massachusetts, 미국, 02190
- Dana Farber Cancer Institute
-
Worcester, Massachusetts, 미국, 01606
- Reliant Medical Group
-
-
Montana
-
Billings, Montana, 미국, 59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry, New Hampshire, 미국, 03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, 미국, 37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, 미국, 37203
- Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, 미국, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford, Texas, 미국, 76022
- Texas Oncology - Bedford
-
Denton, Texas, 미국, 76201
- Texas Oncology - Denton
-
El Paso, Texas, 미국, 79902
- Texas Oncology, P.A.
-
Houston, Texas, 미국, 77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney, Texas, 미국, 75071
- Texas Oncology - McKinney
-
McKinney, Texas, 미국, 75071
- Woodlands Medical Specialists, PA
-
Mesquite, Texas, 미국, 75150
- Woodlands Medical Specialists, PA
-
Plano, Texas, 미국, 75093
- Texas Oncology-Plano West
-
Plano, Texas, 미국, 75075-7787
- Texas Oncology - Plano East
-
San Antonio, Texas, 미국, 78229
- Mays Cancer Center
-
The Woodlands, Texas, 미국, 77380
- US Oncology
-
Tyler, Texas, 미국, 75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray, Utah, 미국, 84107
- Intermountain Medical Center
-
St. George, Utah, 미국, 84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington, Vermont, 미국, 05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester, Virginia, 미국, 22601
- Shenandoah Oncology, P.C.
-
-
-
-
-
Namur, 벨기에, 5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat, Antwerpen, 벨기에, 2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt, Limburg, 벨기에, 3500
- Jessa Ziekenhuis
-
-
-
-
Stockholms
-
Stockholm, Stockholms, 스웨덴, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro, Örebro Län [se-18], 스웨덴, 701 85
- Universitetssjukhuset Örebro
-
-
-
-
-
Badajoz, 스페인, 06006
- Hospital Infanta Cristina
-
Madrid, 스페인, 28009
- Hospital General Universitario Gregorio Marañon
-
Toledo, 스페인, 45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], 스페인, 15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], 스페인, 07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], 스페인, 08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], 스페인, 08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar, Murcia, Región de, 스페인, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga, Málaga, 스페인, 29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona, Navarre, 스페인, 31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus, Tarragona [Tarragona], 스페인, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, 스페인, 46017
- Hospital Universitario Doctor Peset
-
-
-
-
-
San Juan, 아르헨티나, 5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires, Buenos Air, 아르헨티나, C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire, Buenos Air, 아르헨티나, C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA, Buenos Aires F.D., 아르헨티나, 1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, 아르헨티나, 5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, 아르헨티나, 4000
- Centro Medico San Roque
-
-
-
-
Central District
-
Kfar Saba, Central District, 이스라엘, 4428164
- Meir Medical Center
-
Petah Tikva, Central District, 이스라엘
- Rabin Medical Center
-
Ramat Gan, Central District, 이스라엘, 5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, 이스라엘, 9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba, Southern District, 이스라엘, 8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, 이스라엘, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, 이탈리아, 70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto, 이탈리아, 58100
- Ospedale Misericordia di Grosseto
-
Milan, 이탈리아, 20132
- Ospedale San Raffaele
-
Viterbo, 이탈리아, 01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco, Catania, 이탈리아, 95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, 이탈리아, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, 이탈리아, 33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
-
Hradec Králové, 체코, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice, Pardubice Region, 체코, 53203
- Multiscan
-
-
-
-
-
Adana, 터키 (Türkiye), 01370
- Adana City Hospital
-
Ankara, 터키 (Türkiye), 06520
- Memorial Ankara Hastanesi
-
Ankara, 터키 (Türkiye), 06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır, 터키 (Türkiye), 21200
- Dicle Üniversitesi
-
Edirne, 터키 (Türkiye), 22030
- Trakya University
-
Istanbul, 터키 (Türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya, 터키 (Türkiye), 44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram, Konya, 터키 (Türkiye), 42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo, İzmir, 터키 (Türkiye), 009035575
- Izmir Medical Park Hospital
-
-
-
-
Masovian Voivodeship
-
Otwock, Masovian Voivodeship, 폴란드, 05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, 폴란드, 45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, 프랑스, 33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest, Finistère, 프랑스, 29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, 프랑스, 44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon, Vendée, 프랑스, 85000
- CHD Vendee
-
-
-
-
-
Budapest, 헝가리, 1122
- Országos Onkológiai Intézet
-
Budapest, 헝가리, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, 헝가리, 6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, 헝가리, 9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
활성 비교기: Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS)
기간: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
기간: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
기간: Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
간행물 및 유용한 링크
일반 간행물
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 18238
- I3Y-MC-JPEF (기타 식별자: Eli Lilly and Company)
- 2021-002301-10 (EudraCT 번호)
- 2023-506771-10-00 (기타 식별자: EU Trial Number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 공유 기간
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD 공유 액세스 기준
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .